Avant Global

Founder, Chairman and CEO Demetri Argyropoulos leads the firm's investment and relationship strategy. President & COO Justin Figgins, who joined in January 2025, oversees day-to-day operations and corporate development including M&A — he previously executed 30 M&A transactions totaling $7 billion across 13 countries. The website does not name a dedicated Chief Investment Officer.

Avant Global concentrates primarily on pre-seed and seed-stage venture investing. Its model pairs outside operators with select entrepreneurs to commercialize early-stage opportunities. The firm has also pursued growth equity through its White Field Capital Partners collaboration and invests in operating companies and real estate directly.

The firm runs a central database of more than 27,000 connections with a claimed aggregate net worth of over $2 trillion, built over nearly three decades by Demetri Argyropoulos. This network, combined with memberships in YPO and Tiger 21 plus Argyropoulos' advisory roles at Ripple Labs and SandboxAQ, forms the primary sourcing engine.

The firm describes itself as established in 1999 as a single-family office, but today operates as a relationships-driven private investment firm deploying proprietary capital. It does not offer multi-family-office services and does not raise third-party funds, which preserves the economic structure of an SFO even as its behavior resembles a networked principal investor.

Avant Consumer is the firm's consumer-products arm, led by Managing Director Fanis Christodoulou from Greece. Demetri Argyropoulos also serves as General Partner at EQUIAM and co-founded Owl Biomedical, which was acquired by Miltenyi Biotec. These entities operate adjacent to the core Avant Global investing platform.